Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin-based combined modality therapy in PCNSL
NCT00193973Phase 2Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Jul 2001
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of idarubicin in primary central nervous system lymphoma (PCNSL), sponsored by Trans-Tasman Radiation Oncology Group. Started Jul 2001; status: completed.
02
Drugs
idarubicin
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00193973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193973.